Kirkland Advises Boehringer in Agreement to Sell Roxane Laboratories

Kirkland & Ellis LLP advised Boehringer Ingelheim Corporation, one of the world’s leading privately held pharmaceutical companies, in an agreement to sell its U.S. generics business, Roxane Laboratories Inc., to Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK), for $1.18 billion in cash and 40 million new Hikma shares. The total value of the consideration payable at closing is approximately $2.65 billion.

The Kirkland team was led by corporate partners Sean Rodgers, Shawn O’Hargan, Patrick Jacobs and David Fox.